Except where otherwise noted, this item's license is described as Creative Commons Attribution – Non Commercial
Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA
- QMRO Home
- William Harvey Research Institute
- Centre for Clinical Pharmacology
- Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA
- QMRO Home
- William Harvey Research Institute
- Centre for Clinical Pharmacology
- Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA
Browse
Administrators only
Statistics
